SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, promotes Amy VandenBerg to Chief Clinical and Regulatory Affairs Officer. Ms. VandenBerg joined Obalon in December of 2008, served as Vice President of Clinical and Regulatory Affairs since November of 2014, and was Vice President of Regulatory Affairs since February of 2012.
“Amy led the clinical and regulatory aspects for FDA approval of Obalon’s original PMA and recent PMA-S approval of the Navigation/Touch system. She continues to lead across all functions and levels of the organization. I am pleased to recognize Amy’s contributions to the current business and future pipeline with her promotion to Chief Clinical & Regulatory Affairs Officer,” said CEO Kelly Huang, Ph.D.
Prior to joining Obalon, Ms. VandenBerg held positions of increasing leadership at other medical device companies, including Dexcom, Inc. and Cygnus. She has more than 20 years of experience bringing novel, disruptive medical device technologies from the research and development phase through the US FDA PMA approval process.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics' future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the product research, development and regulatory process and risks. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics' business in general, please refer to Obalon Therapeutics’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2018, and its current and future periodic reports filed with the Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103